Bayer AG BAYN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BAYN is a good fit for your portfolio.
News
-
Bayer to Launch Ten Blockbuster Agriculture Products in the Next Decade
-
Bayer's Lung Cancer Drug Gets Breakthrough Therapy Status in China
-
Trending: Bayer-Owned Monsanto's Roundup Case Payment Cut to $400 Million
-
Monsanto's Weedkiller Payout Slashed to $400 Million From $2.25 Billion
-
Bayer Subsidiary Gets Fast-track Status for Parkinson's Treatment in U.S.
-
Robert F. Kennedy Jr. invests $24,000 in GameStop in apparent play for ape vote
-
Bayer Plans More Job Cuts in Push for Fewer Bosses — Update
-
Bayer Net Profit Falls on Lower Sales, Currency Headwinds
Trading Information
- Previous Close Price
- €26.09
- Day Range
- €25.69–26.15
- 52-Week Range
- €24.98–—
- Bid/Ask
- €25.67 / €25.68
- Market Cap
- €25.23 Bil
- Volume/Avg
- 2,817 / 3.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 4.58
- Price/Sales
- 0.55
- Dividend Yield (Trailing)
- 0.42%
- Dividend Yield (Forward)
- 0.42%
- Total Yield
- 0.42%
Company Profile
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 99,723
- Website
- https://www.bayer.com
Competitors
Valuation
|
Metric
|
BAYN
|
BASFY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 4.58 | 19.76 | 19.49 |
Price/Book Value | 0.72 | 1.08 | 1.72 |
Price/Sales | 0.55 | 0.60 | 2.86 |
Price/Cash Flow | 3.41 | 7.10 | 18.38 |
Price/Earnings
BAYN
BASFY
PFE
Financial Strength
|
Metric
|
BAYN
|
BASFY
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.87 | 1.23 | 0.67 |
Current Ratio | 1.31 | 2.09 | 1.05 |
Interest Coverage | 0.04 | 1.74 | −0.26 |
Quick Ratio
BAYN
BASFY
PFE
Profitability
|
Metric
|
BAYN
|
BASFY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 5.13% | 1.18% | 3.77% |
Return on Equity (Normalized) | 17.12% | 2.55% | 8.51% |
Return on Invested Capital (Normalized) | 9.36% | 2.29% | 5.75% |
Return on Assets
BAYN
BASFY
PFE
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Nrvhmkyyz | Hmrf | $826.6 Bil | |||
| Johnson & Johnson
JNJ
| Nqhhktmvm | Vpqnd | $350.1 Bil | |||
| Merck & Co Inc
MRK
| Zxmgdkfm | Mdhf | $318.6 Bil | |||
| AbbVie Inc
ABBV
| Hsntmxzl | Zxsln | $294.1 Bil | |||
| AstraZeneca PLC ADR
AZN
| Pqssnsgkxf | Mjsx | $239.1 Bil | |||
| Novartis AG ADR
NVS
| Pvjfjbwl | Vhcx | $221.6 Bil | |||
| Roche Holding AG ADR
RHHBY
| Qpgmbtxtq | Mhv | $219.9 Bil | |||
| Amgen Inc
AMGN
| Dqllxkvjl | Zzlj | $167.1 Bil | |||
| Pfizer Inc
PFE
| Mzpwdtzn | Fngrn | $158.3 Bil | |||
| Sanofi SA ADR
SNY
| Lbdwhdryw | Cdyd | $124.7 Bil |